RSSDI Repository, Complications of Diabetes Demonstration
RSSDI Repository, Complications of Diabetes Demonstration

Have a Question?

If you have any question you can ask below or enter what you are looking for!

Advanced Search
  • Home/
  • Article /
  • Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study.

Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study.

Add to Collection
2020 Dec 3 Observational studies O Goyal, S Nohria, P Goyal, J Kaur, S Sharma… - Scientific reports, 2020 - nature.com

Full Author : ['Goyal, Omesh', 'Nohria, Sahil', 'Goyal, Prerna', 'Kaur, Jaskirat', 'Sharma, Sarit', 'Sood, Ajit', 'Chhina, Rajoo Singh']
Journal Title : Scientific reports
Chapter : Section2
Journal Year : 2020
Cited by : 35

Saroglitazar, a dual peroxisome proliferator activated receptor alpha/gamma agonist, approved for diabetic dyslipidemia (DD), is potential therapeutic option for non-alcoholic fatty liver disease (NAFLD). This prospective, observational, real-world study ..... Read More

Keywords : ['prospective observational real world study', 'nonalcoholic fatty liver disease', 'diabetic dyslipidemia', 'saroglitazar', 'patient']
PubMed Link : https://www.nature.com/articles/s41598-020-78342-x
Google Scholar Link : https://scholar.google.com/scholar?cites=11645444056246885455&as_sdt=8005&sciodt=0,7&hl=en&num=20